Redmile Group LLC Makes New Investment in Eupraxia Pharmaceuticals Inc. $EPRX

Redmile Group LLC acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the first quarter, HoldingsChannel reports. The fund acquired 700,000 shares of the company’s stock, valued at approximately $5,068,000.

Several other large investors have also recently made changes to their positions in EPRX. Rubric Capital Management LP acquired a new position in Eupraxia Pharmaceuticals during the 1st quarter valued at about $5,004,000. SummitTX Capital L.P. boosted its stake in Eupraxia Pharmaceuticals by 86.4% in the 1st quarter. SummitTX Capital L.P. now owns 327,997 shares of the company’s stock worth $2,375,000 after purchasing an additional 152,049 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after purchasing an additional 1,289,005 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth $122,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter worth $4,606,000.

Analyst Ratings Changes

A number of analysts have commented on EPRX shares. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Stifel Nicolaus began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a “buy” rating and a $25.00 price objective for the company. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Eupraxia Pharmaceuticals Trading Down 1.1%

Shares of Eupraxia Pharmaceuticals stock opened at $6.10 on Wednesday. The firm has a 50-day simple moving average of $6.50 and a two-hundred day simple moving average of $7.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. Eupraxia Pharmaceuticals Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $9.32. The company has a market cap of $396.62 million, a P/E ratio of -5.81 and a beta of 1.05.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). As a group, equities analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.88 earnings per share for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.